Cardiogenic shock with non-ST-segment elevation myocardial infarction: a report from the SHOCK Trial Registry
Alice K. Jacobs, MD, FACC*,
John K. French, PhD, MBChB ,
Jacques Col, MD ,
Lynn A. Sleeper, ScD ,
James N. Slater, MD, FACC||,
Louis Carnendran, MD||,
Jean Boland, MD¶,
Xianjiao Jiang, MS ,
Thierry LeJemtel, MD, FACC**,
Judith S. Hochman, MD, FACC|| for the SHOCK Investigators
* Department of Medicine, Boston Medical Center, Boston, Massachusetts, USA
Green Lane Hospital, Auckland, New Zealand
Cliniques Universitaires, Brussels, Belgium
New England Research Institutes, Watertown, Massachusetts, USA
|| St. LukesRoosevelt Hospital, New York, New York, USA
¶ CHR Citadelle, Liège, Belgium
** Albert Einstein College of Medicine, Bronx, New York, USA

View larger version (11K):
[in a new window]
|
Figure 1 Severity of coronary vessel disease in patients with shock due to LV failure undergoing coronary angiography. No or single-, double-, triple-vessel disease: n = 73 for non-ST-segment elevation and n = 443 for ST-segment elevation MI; left main disease: n = 72 for non-ST-segment elevation and n = 434 for ST-segment elevation MI.
|
|

View larger version (11K):
[in a new window]
|
Figure 2 Rates of in-hospital coronary angiography and revascularization after the diagnosis of CS caused by LV failure. CABG = coronary artery bypass surgery; PTCA = percutaneous transluminal coronary angioplasty.
|
|
|